FDA Approves New Breast Cancer Pill Guided by Blood Test

The U.S. Food and Drug Administration has approved a new oral treatment for certain adults with advanced breast cancer, introducing a treatment strategy that uses a blood test to detect signs of drug resistance before scans show that the cancer has started growing.

The FDA granted accelerated approval on September 4, 2026, to Etcamah (camizestrant), made by AstraZeneca. The medicine is approved for use with one of three CDK4/6 inhibitors: abemaciclib, palbociclib, or ribociclib. It is intended for adults with hormone receptor positive, HER2-negative, locally advanced or metastatic breast cancer whose tumors develop an ESR1 mutation while they are receiving an aromatase inhibitor and a CDK4/6 inhibitor.

The approval is notable because doctors can use a blood-based test to identify an emerging resistance mutation and potentially change treatment before conventional imaging confirms that the cancer is progressing.

What Is Etcamah?

Etcamah, also known by its generic name camizestrant, is an oral estrogen receptor antagonist. The recommended dose is 75 milligrams taken once daily, with or without food, in combination with a CDK4/6 inhibitor. Treatment continues until the disease progresses or side effects become unacceptable.

The drug is designed for a specific type of advanced breast cancer. These cancers are hormone receptor positive, meaning their growth can be driven by hormones such as estrogen, and they are HER2-negative.

Hormone therapy is commonly used to control these cancers. Aromatase inhibitors work by reducing the body's production of estrogen, helping deprive cancer cells of a hormone they may need to grow.

However, breast cancer can evolve during treatment. One mechanism of resistance involves changes in the ESR1 gene, which provides instructions for the estrogen receptor. When an ESR1 mutation develops, cancer cells may become less responsive to certain endocrine treatments.

How the Blood Test Can Detect Treatment Resistance

The FDA also authorized the Guardant360 CDx test as a companion diagnostic for identifying patients with breast cancer who have ESR1 mutations and may be eligible for camizestrant. The test analyzes circulating tumor DNA, often called ctDNA, found in a patient's blood.

Cancer cells can release small fragments of DNA into the bloodstream. By analyzing those fragments, doctors may be able to identify genetic changes associated with treatment resistance.

This approach can provide information at the molecular level before changes become obvious on a CT scan or other imaging study.

The FDA described the approval as the first cancer therapy approval guided by detection of a resistance mutation in circulating tumor DNA before imaging tests show disease progression. At the same time, the agency emphasized that additional evidence is needed to determine whether acting on this molecular signal before radiographic progression provides a meaningful long-term clinical benefit.

What the Clinical Trial Found

The approval was based on results from the Phase 3 SERENA-6 clinical trial. The study included 315 adults with hormone receptor positive, HER2-negative locally advanced or metastatic breast cancer who had been receiving an aromatase inhibitor and a CDK4/6 inhibitor as initial endocrine-based treatment.

Participants had detectable ESR1 mutations identified through blood-based circulating tumor DNA testing while there was no evidence of disease progression according to investigator assessment.

Patients were randomly assigned either to switch to camizestrant while continuing their CDK4/6 inhibitor or to continue their existing aromatase inhibitor with the CDK4/6 inhibitor.

The median progression-free survival was 16 months for patients who received camizestrant with a CDK4/6 inhibitor, compared with 9.2 months for those who continued an aromatase inhibitor with a CDK4/6 inhibitor.

Progression-free survival refers to the amount of time during which patients live without their cancer getting worse.

The FDA reported a hazard ratio of 0.44, meaning the camizestrant treatment strategy was associated with a substantially lower risk of disease progression or death during the analysis. Overall survival data were not yet mature at the time of the progression-free survival analysis.

AstraZeneca has reported that the treatment strategy reduced the risk of disease progression or death by 56% in the SERENA-6 trial.

Why This Approval Matters

Traditional cancer monitoring often relies on imaging to determine whether a tumor is growing. By the time progression becomes visible, a resistant cancer may already have had time to expand.

The strategy behind Etcamah is different. Instead of waiting for visible progression, doctors can monitor the cancer's genetic changes through a blood test.

If an ESR1 mutation appears, the treatment can be changed while the cancer is still considered clinically stable.

This represents a growing role for liquid biopsy testing in cancer treatment. Rather than using blood tests only to monitor general health, physicians can use circulating tumor DNA to look for specific molecular changes that may influence treatment decisions.

The FDA noted that additional studies are necessary to confirm whether this earlier intervention ultimately translates into a clinically meaningful benefit for patients.

Etcamah Safety Warnings

Like other cancer medicines, camizestrant carries important safety considerations.

The FDA prescribing information includes a boxed warning concerning the risk of abnormal heart rhythms related to QTc interval prolongation when camizestrant is taken with certain medications that can also prolong the QT interval.

The drug also carries warnings and precautions concerning bradycardia, which means an abnormally slow heart rate, and embryo-fetal toxicity.

Patients considering camizestrant should discuss their other medications and medical conditions with their oncology team. Treatment decisions should be based on the individual's cancer characteristics, previous therapies, genetic test results, and overall health.

What Accelerated Approval Means

Etcamah received accelerated approval, an FDA pathway used for certain serious conditions when preliminary evidence suggests that a treatment may provide a meaningful benefit.

Accelerated approval does not necessarily mean that every potential benefit of a medicine has been definitively established.

In this case, the FDA based the approval on progression-free survival results and requires additional evidence to verify and describe clinical benefit. Continued approval of the indication may depend on the results of confirmatory studies.

That distinction is important for patients and families. The trial showed that switching to camizestrant after detection of an ESR1 mutation delayed disease progression compared with continuing aromatase inhibitor treatment. However, researchers still need to establish whether this earlier treatment change improves longer-term outcomes such as overall survival.

A New Approach to Advanced Breast Cancer Treatment

The FDA's approval of Etcamah adds another option for people with advanced hormone receptor positive, HER2-negative breast cancer whose tumors develop ESR1 mutations during treatment.

More importantly, the decision highlights how cancer care is becoming increasingly personalized. A blood sample can reveal a genetic change inside a tumor, and that information can help doctors decide whether it is time to change treatment.

For patients with advanced breast cancer, the goal is not simply to find another drug after a scan shows progression. The emerging strategy is to identify resistance as early as possible and respond before the disease becomes visibly worse.

Further research will determine how broadly this approach can improve outcomes. For now, the Etcamah approval represents an important step toward using molecular information from a blood test to guide treatment decisions in advanced breast cancer.

Sources

• U.S. Food and Drug Administration, “FDA Grants Accelerated Approval to a New Breast Cancer Treatment,” September 4, 2026.
• U.S. Food and Drug Administration, “FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer,” September 4, 2026.
• AstraZeneca, “Etcamah (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer,” September 4, 2026.

Disclaimer

This article is for informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. FDA approvals, clinical evidence, treatment recommendations, and prescribing information can change. Patients with breast cancer should speak with their oncologist or another qualified healthcare professional about whether camizestrant or another treatment is appropriate for their individual circumstances.